AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ROSUVASTATIN;EZETIMIBE

9 registrations across 3 African markets— 9 active

Markets with ROSUVASTATIN;EZETIMIBE

Recent registrations

Brand / ProductMarketHolderStatusExpires
ROSTATIN Z 10/20
CAPSULE; ORAL
🇿🇼ZimbabweCOSPHARM INVESTMENTS PVT LTDactiveMar 2031
ROSTATIN Z 10/10
CAPSULE; ORAL
🇿🇼ZimbabweCOSPHARM INVESTMENTS PVT LTDactiveMar 2031
Rovista EZ Tablets 20mg+10mg
Film-Coated Tablet
🇰🇪KenyaGetz Pharma (Pvt.) LimitedactiveMar 2029
Rovista EZ Tablets 10mg+10mg
Film-Coated Tablet
🇰🇪KenyaGETZ PHARMA (PRIVATE) LIMITEDactiveMar 2029
Rovista EZ Tablets 5mg+10mg
Film-Coated Tablet
🇰🇪KenyaGETZ PHARMA (PRIVATE) LIMITEDactiveMar 2029
ROSUZET 20 mg/10 mg🇿🇦South AfricaCipla Medpro (Pty) LtdactiveNov 2027
ROSUZET 40 mg/10 mg🇿🇦South AfricaCipla Medpro (Pty) LtdactiveNov 2027
ROSUZET 5 mg/10 mg🇿🇦South AfricaCipla Medpro (Pty) LtdactiveNov 2027
ROSUZET 10 mg/10 mg🇿🇦South AfricaCipla Medpro (Pty) LtdactiveNov 2027

ROSUVASTATIN;EZETIMIBE in Africa — Regulatory Overview

ROSUVASTATIN;EZETIMIBE is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Kenya, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.